Abstract
A double-blind, randomized, controlled trial involving 706 adults was conducted to evaluate the immunogenicity and safety of different dosages of whole-virion or split-virion H1N1 influenza vaccines with or without aluminum adjuvant. A rapid and strong immune response was induced at day 14 after the first injection. The seroprotection rates ranged from 72.7% (95% confidence interval [CI], 62.7%-81.1%) for 5-microg whole-virion aluminum formulation to 97.0% (95% CI, 90.9%-99.7%) for 30-microg split-virion nonaluminum formulation. All formulations were well tolerated. The incidences of mild, moderate, and severe reactions were 71 (10.1%), 15 (2.1%), and 1 (0.1%) of 706 reactions, respectively. The 15-microg split-virion formulation had the best immunogenicity and safety.
Citations
Sep 19, 2012·Medical Microbiology and Immunology·R AllwinnI Friedrichs
May 22, 2013·BMC Infectious Diseases·Jiří BeranJeanne-Marie Devaster
Nov 19, 2013·BMC Infectious Diseases·Ma Teresa HerreraMartha Torres
Sep 15, 2011·PloS One·Lamberto ManzoliJohn P A Ioannidis
Jul 19, 2011·Emerging Infectious Diseases·James E FieldingHeath A Kelly
Dec 4, 2012·Viruses·Jessica A ChichesterVidadi Yusibov
Oct 16, 2013·Vaccine·James F CummingsUNKNOWN Fraunhofer USA Center for Molecular Biotechnology Study Group
Jun 4, 2015·Emerging Microbes & Infections·Zhenglun LiangJunzhi Wang
Jun 15, 2011·Influenza and Other Respiratory Viruses·J Kevin YinRobert Booy
Nov 9, 2012·Influenza and Other Respiratory Viruses·Yan-Ping LiWei-Dong Yin
Apr 18, 2012·Vaccine·Tetsuo NakayamaToshiaki Ihara
Jul 17, 2013·Vaccine·William H YangDavid W Vaughn
May 29, 2012·Vaccine·Wei LiuWu-Chun Cao
Dec 21, 2010·Vaccine·M LoebermannE C Reisinger
May 6, 2015·The Cochrane Database of Systematic Reviews·Christine ClarKaren Rees
Dec 10, 2014·Expert Review of Vaccines·Vidadi YusibovStephen J Streatfield
Sep 9, 2011·Clinical Trials : Journal of the Society for Clinical Trials·David W ScheifeleScott A Halperin
Feb 24, 2015·Expert Review of Vaccines·Miao XuJunzhi Wang